FDA approves clinical study in Alzheimer patients

Today, FDA approved the first clinical study with BAN2401 in Alzheimer patients. BAN2401 is a humanized monoclonal antibody targeting the toxic protofibrils in Alzheimer´s disease. ...

BioArctic receives milestone

BioArctic receives 1st milestone payment from Eisai. In December 2007, BioArctic Neuroscience AB signed an exclusive license agreement with Eisai Co., Ltd, where first milestone payment ...

US vaccination patent approved

BioArctic s US patent on an Alzheimer vaccine was approved today. BioArctic Neuroscience AB has a proprietary technological platform for immunotherapy against misfolded proteins.

BioArctic rewarded

Today, VINNOVA announced that BioArctic Neuroscience AB was granted 1.9 million SEK for development of its proprietary product with the indication Treatment of Traumatic Spinal Cord ...